Sogroya® (somapacitan-beco) – Expanded indication, new dosage strength
April 28, 2023 - FDA approved NovoNordisk’s Sogroya (somapacitan-beco), for the treatment of pediatric patients aged 2.5 years and older who have growth failure due to inadequate secretion of endogenous growth hormone (GH).
Download PDF
